Minimal change glomerular disease associated with solid neoplasms: a systematic review.
Cozzo D, Orlando F, Bruno M, Ogna A, Forni Ogna V.
J Nephrol. 2025 Mar;38(2):343-352. doi: 10.1007/s40620-024-02084-6. Epub 2024 Oct 1.
Onco-nephrology: glomerular diseases with cancer.
Cambier JF, Ronco P.
Clin J Am Soc Nephrol. 2012 Oct;7(10):1701-12. doi: 10.2215/CJN.03770412. Epub 2012 Aug 16.
Paraneoplastic glomerulopathies.
Norris SH.
Semin Nephrol. 1993 May;13(3):258-72.
[Paraneoplastic autoimmune disorders].
Hirokawa M.
Gan To Kagaku Ryoho. 2010 Jun;37(6):980-3.
Glomerular injury in patients with neoplasia.
Kaplan BS, Klassen J, Gault MH.
Annu Rev Med. 1976;27:117-25. doi: 10.1146/annurev.me.27.020176.001001.
Membranous nephropathy-one morphologic pattern with different diseases.
Hoxha E, von Haxthausen F, Wiech T, Stahl RAK.
Pflugers Arch. 2017 Aug;469(7-8):989-996. doi: 10.1007/s00424-017-2000-4. Epub 2017 May 29.
Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate.
Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C.
Ren Fail. 1998 Mar;20(2):295-302. doi: 10.3109/08860229809045114.
Wilms tumor and the WT1 gene.
Lee SB, Haber DA.
Exp Cell Res. 2001 Mar 10;264(1):74-99. doi: 10.1006/excr.2000.5131.
Tumor marker elevations in chronic kidney disease: a retrospective study.
You L, Xu Z, Liu Q, Jin G, Wang C.
PeerJ. 2025 Apr 3;13:e19240. doi: 10.7717/peerj.19240. eCollection 2025.
Tumor Stimulus-Responsive Biodegradable Diblock Copolymer Conjugates as Efficient Anti-Cancer Nanomedicines.
Šubr V, Pola R, Gao S, Islam R, Hirata T, Miyake D, Koshino K, Zhou JR, Yokomizo K, Fang J, Etrych T.
J Pers Med. 2022 Apr 27;12(5):698. doi: 10.3390/jpm12050698.
